Jubilant Life Sciences net profit falls 10 percent to Rs 224 crore in Q2
Advertisement
New Delhi: Drug firm Jubilant Life Sciences on Wednesday reported a 10.13 percent decline in its consolidated net profit to Rs 224.12 crore for the quarter ended September, mainly on account of higher taxes.
The company had posted a net profit of Rs 249.39 crore for the corresponding period of the previous fiscal, Jubilant Life Sciences said in a BSE filing.
Total revenue from operations stood at Rs 2,374.89 crore for the quarter under consideration. It was Rs 2,265.93 crore for the same period a year ago, it added.
With the strong demand recovery and new business sign-ups, "we expect strong performance in our Pharma, Life Science Ingredients (LSI) and Drug Discovery & Development Solutions (DDDS) businesses in the H2''FY21," they added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.